MedTrace Logo

Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy

NCT05371249 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 628

Last updated 2023-08-07

No results posted yet for this study

Summary

This study aims to compare the efficacy of the current standard first-line anti-helicobacter pylori regimen, extended proton pump inhibitor-based sequential therapy, with that of vonoprazan-based triple therapy, through a randomized controlled trial.

Conditions

  • Helicobacter Pylori

Interventions

DRUG

Vonoprazan-based triple therapy

vonoprazan 20mg+amoxicillin 1000 mg + clarithromycin 500 mg twice daily for seven days

DRUG

Extended sequential therapy

Lansoprazole 30mg + amoxicillin 1000mg twice daily for 7 days, followed by lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg twice daily for 7 days

Sponsors & Collaborators

  • Fu Jen Catholic University Hospital

    lead OTHER

Principal Investigators

  • Yu-tse Chiu, MD · Fu Jen Catholic University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2023-12-30
Completion
2024-02-28

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05371249 on ClinicalTrials.gov